Figure 2. LAMPS reproducibility with respect to the (A) functional performance, (B) metabolic capacity, and (C) drug-induced effects across different laboratories. Experiments were performed in parallel in two laboratories (1=circles and 2=squares) independently, but using the same protocols and the same batch of primary human hepatocytes.
| View/Edit | Study Name | Start Date | Study Types | Experimental Models | Model Types | Disease(s) | Data Points | Data Points (omic) | Images | Videos | Plate Maps | Plate Reader Files | Supporting Data Files | Description | Reproducibility Status | Center | Data Entry | Review | Sign Off Date | Data Provider | ID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| View/Edit | EPA 2 | 2016-09-15 | TOX | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 343 | 0 | 0 | 0 | 0 | 0 | 0 | Eighteen day study assessing the the toxicity of Caffeine, Valproic Acid, Thalidomide, and Warfarin. | UPDDI | Dillon Gavlock | 4 | 2019-07-16 | Taylor_EPA | 120 | |
| View/Edit | EPA 4 | 2016-10-13 | TOX | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 356 | 0 | 0 | 0 | 0 | 0 | 0 | Eighteen day study assessing toxicity of Erythromycin, Famotidine, Levofloxacin, Rosglitazone, and Trovafloxcin. | UPDDI | Dillon Gavlock | 4 | 2019-07-16 | Taylor_EPA | 122 | |
| View/Edit | EPA 1 | 2016-08-04 | TOX | SQL-SAL 1.5 | Fluidic-3D | -No Diseases- | 256 | 0 | 0 | 0 | 0 | 0 | 0 | 3 week study comparing Tolcapone and Entacapone | UPDDI | Albert Gough | 4 | 2019-08-06 | Taylor_EPA | 117 |